Young enteric microorganism phytobacterium gasseri Y11 and application of young enteric microorganism phytobacterium gasseri Y11
By screening and identifying Lactobacillus glandin Y11 in the youth-derived intestine, the problem of poor treatment effect of type II diabetes and limited development of synbiotic products in the prior art was solved, and the glycemic effect in the mouse model was achieved New strategies for product development of Hemobile Bioscience.
Patent Information
- Application Number
- CN202411367018.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-29
- Publication Date
- 2024-12-06
AI Technical Summary
The prior art cannot effectively treat type II diabetes, and drug treatment has side effects, and the development of traditional synbiotic products is limited by the problem of poor synergistic effects between prebiotics and probiotics.
Lactobacillus Grignard Y11, which is acid-resistant, bile salt and gastric juice, was screened from the youth source intestine. It was identified through 16S rDNA sequencing and combined with physiological and biochemical tests to determine its glucose-lowering properties, and verified in high-fat and high-sugar model mice. Lowering sugar mechanism.
Lactobacillus Grignard Y11 improves blood lipid metabolism and blood glucose homeostasis, regulates related gene expression, increases the abundance of Bifidobacterium, provides a new direction for diabetes treatment, and provides a rapid screening strategy for the development of synbiotic products.
Smart Images

Figure CN119081960A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of microorganisms, and in particular relates to a youth-derived intestinal microorganism Lactobacillus gasseri Y11 and an application thereof. Background Art
[0002] With the improvement of modern people's living standards and quality of life, high-fat and high-sugar foods have gradually entered ordinary families, and food safety issues have become more and more serious, leading to the gradual spread of some chronic metabolic diseases, among which type 2 diabetes is a typical chronic metabolic disease. According to statistics from the World Health Organization, by 2050, patients with type 2 diabetes will gradually become younger, and many young people will suffer from type 2 diabetes, but modern technology cannot cure it, and its pathogenesis has not yet been cured. It can only be treated with drugs. Since drug treatment will produce some side effects, such as abdominal pain, flatulence, diarrhea, vomiting, etc., finding a safe and effective new method is an urgent task at present. As natural microecological preparations and synbiotic products have entered people's field of vision, their safety and reliability have gradually been recognized by the public.
[0003] Supplementation of probiotics can improve carbohydrate metabolism and reduce metabolic stress in patients with T2DM. After taking synbiotics, the blood lipid profile of patients with type II diabetes is improved. The synergy between prebiotics and probiotics has been proven to improve T2DM, and the combination of synbiotics is currently a hot topic of research. The traditional synbiotic screening strategy is to find synergistic prebiotics through probiotics. Due to the small number of prebiotics and the suboptimal effect after combination, the development of synbiotic products is restricted. This study uses prebiotic oligosaccharides to find synergistic probiotics, thereby expanding the types and number of probiotics, increasing the chance of their synergy, and achieving a fast and convenient way to develop synbiotic products. Summary of the invention
[0004] The present invention isolates a series of lactic acid strains from the intestines of young people, and screens out a lactic acid bacteria with potential hypoglycemic properties by taking acid resistance, bile salts, artificial gastric juice, artificial intestinal juice, antibacterial activity, α-amylase, α-glucosidase, etc. as indicators. The bacteria is preliminarily identified by sequencing its 16S rDNA, and then determined to be Lactobacillus gasseri based on the results of physiological and biochemical tests, and named Y11. The hypoglycemic mechanism of the strain in type 2 diabetic mice induced by a high-fat and high-sugar diet and streptozotocin is further evaluated through in vivo experiments.
[0005] A youth-derived intestinal microorganism Lactobacillus gasseri Y11, the preservation number of the Lactobacillus gasseri Y11 is CGMCC No.31108.
[0006] The invention relates to an application of the Lactobacillus gasseri Y11 in the preparation of a hypoglycemic drug.
[0007] A blood sugar lowering drug comprising the Lactobacillus gasseri Y11.
[0008] A fermentation product is obtained by fermenting Lactobacillus gasseri Y11.
[0009] A prebiotic, comprising the Lactobacillus gasseri Y11 and / or a fermentation product thereof.
[0010] The Lactobacillus gasseri Y11 of the present invention is classified and named Lactobacillus gasseri, and is deposited in the General Microbiology Center (CGMCC) of the China Culture Collection Administration of Microorganisms on June 27, 2024, with a deposit number of CGMCC No.31108, and a deposit address of No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing.
[0011] Beneficial effects of the present invention: The present invention is based on a new method for prebiotic enrichment, probiotic separation, purification and screening of synbiotics, and screens and identifies Lactobacillus gasseri Y11 with hypoglycemic properties. The present invention's Lactobacillus gasseri Y11 is separated from the youth source intestine, has good acid resistance, bile resistance and tolerance to artificial gastrointestinal fluid, and has good inhibitory activity of alpha-amylase and alpha-glucosidase; taking high-fat and high-sugar model and streptozotocin-induced type 2 diabetic mice as models, Lactobacillus gasseri Y11 can improve blood lipid metabolism indexes and blood glucose homeostasis, regulate the expression of peroxisome proliferator-activated receptor γ (PPARγ), phosphoenolpyruvate carboxykinase (PEPCK), glucose-6-phosphatase (G6PASE), MTOR-S6K1, glucose transporter 2 (GLUT-2) genes in the ileum and liver, and in addition, in addition to the host's metabolic characteristics, 16S rRNA gene sequencing is also used to analyze the intestinal microbiome and find that the relative abundance of bifidobacteria is significantly increased, and Mantel test and Spearman correlation analysis are used to analyze the association between intestinal flora and serum indicators and genes. The present invention emphasizes a synbiotic screening strategy, explores its potential application in diabetes treatment, and provides a new research direction for anti-diabetic mechanisms. BRIEF DESCRIPTION OF THE DRAWINGS
[0012] Figure 1For the screening of probiotics.
[0013] Figure 2 Morphology and developmental tree of strain 11.
[0014] Figure 3 The animal experiment groups and the changes in body weight, fasting blood glucose, OGTT and AUC between different groups.
[0015] Figure 4 These are the lipid levels, glycosylated hemoglobin levels and insulin levels in the serum of mice in different treatment groups.
[0016] Figure 5 H&E staining of mouse liver sections.
[0017] Figure 6 is the expression level of related genes in liver and ileum.
[0018] Figure 7 For intestinal flora analysis (AB).
[0019] Figure 8 This is the intestinal flora analysis (CD).
[0020] Fig. 9 For intestinal flora analysis (EF). DETAILED DESCRIPTION
[0021] Example 1 Screening by prebiotic enrichment and evaluation of functionality and prebiotic properties
[0022] Use a sterile cotton swab to collect fresh intestinal microbial samples from volunteers, and immediately place them in an ice box, and then quickly place them in an ultra-low temperature refrigerator for later use. Take 1 gram of fresh feces and add it to 9 mL of sterilized XOS-MRS medium, shake it evenly, and make 10 -1 of fecal dilution, draw 1 mL 10 -1 Dilute the stool into 9 mL PBS to make 10 -2 The fecal dilution was serially diluted to 10 with PBS. -7 , 37℃ for 48h. After 5 subcultures, 0.1mL of the dilution solution was aspirated and mixed on XOS-MRS for 48h at 37℃. The number and state of the bacterial colony were observed, and single colonies of different shapes and sizes were picked and purified continuously on XOS-MRS.
[0023] (1) Determination of the inhibition rate of probiotics on α-glucosidase
[0024] Lactobacillus was cultured in XOS-MRS medium at 37°C, then centrifuged at 4°C, 8000r / min, 15 minutes to collect the strains, washed twice with sterile (0.1mol / LpH 6.8) PBS, and then resuspended with PBS to adjust the bacterial concentration to 1×109CFU / mL. A portion of the resuspended solution was incubated at 37°C for 12 hours to obtain extracellular secretions, and then at 4°C, 8000r / min, 15 minutes to remove bacterial cells. Finally, the supernatant was filtered through a 0.22μm filter membrane to obtain the extracellular supernatant (CFS); the other part of the resuspended solution was ultrasonically broken under ice bath conditions. The conditions for ultrasonic disruption were: power 200W, pulse disruption 3–8 seconds (working 3 seconds, stopping 8 seconds) for 15 minutes, and then centrifuged at 4°C, 11000r / min, 20 minutes, and the supernatant was filtered through a 0.22μm filter membrane to obtain a cell-free extract (CFE).
[0025] (2) Determination of the inhibition rate of probiotics on α-amylase
[0026] 1U / mL amylase was added to PBS to a volume of 250mL, and the solution was dissolved by magnetic stirrer for 30min. The upper layer was used for use. After the strain was activated for three generations, it was centrifuged at 4℃ and 8000r / min for 10min. The supernatant was taken, amylase, soluble starch, and DNS were added, boiled for 5min, and then diluted 20 times. The OD was measured at 540nm by microplate reader.
[0027] (3) Acid resistance evaluation
[0028] A certain concentration of bacterial suspension (1×10 9 CFU / mL) was inoculated into the acid-resistant XOS-MRS medium with a pH of 3.0 at a 1% inoculation rate and cultured at 37°C. Samples were taken at 0 and 3 hours, respectively, and the number of viable bacteria was determined by the plate count method.
[0029] (4) Bile salt tolerance evaluation
[0030] A certain concentration of bacterial suspension (1×10 9 CFU / mL) was inoculated into XOS-MRS liquid culture medium supplemented with 3.0 g / L ox bile salt and 2.0 g / L thioglycolic acid at a 1% inoculation rate and cultured at 37°C. Samples were taken at 0 and 4 hours, respectively, and the number of viable bacteria was determined by plate counting method.
[0031] (5) Evaluation of resistance to gastrointestinal juice
[0032] Adjust the pH of PBS to 3.0 and 8.0, and add appropriate amounts of pepsin and trypsin to prepare artificial gastrointestinal fluid. Use dilute hydrochloric acid and sodium hydroxide to adjust the acid and alkalinity. Inoculate the bacterial suspension at a 1% inoculum volume, culture in artificial gastric fluid for 3 hours, and calculate the number of viable bacteria. Take out 1 mL of the bacterial suspension after 3 hours of culture in artificial gastric fluid and add it to artificial intestinal fluid for 7 hours, calculate the number of viable bacteria, and finally calculate the survival rate of the strain in artificial gastrointestinal fluid.
[0033] The strains were enriched from 7 intestinal microbial samples using modified MRS medium (XOS-MRS). It was previously found that the relative abundance and diversity of the intestinal flora in the samples remained stable after the fifth enrichment passage, so this was selected as the basis for enrichment screening ( Figure 1 A). As a result, 105 probiotic strains were obtained (only some representative strains were shown in the study). Blood sugar lowering screening was performed by screening for α-glucosidase and α-amylase ( Figure 1 BD). Evaluation of tolerance of potential strains (pH, bile salts, gastrointestinal fluids) Figure 1 EG) to identify potential strains11.
[0034] Example 2 Identification of probiotic strains
[0035] The morphology of the continuously purified strains was observed, and the size, color, and gloss of the colonies were recorded. Gram staining was performed and the strain morphology was observed under a microscope. The bacterial genomic DNA was extracted with reference to the phenol-chloroform method. The reaction system was: 27F (5'-GAGTTTGATCCTGGCTCA-3') 1μL, 1492R (5'-TACCTTGTTACGACTT-3') 1μL, 2×Taq PCR Master Mix 12.5μL, genomic DNA 1μL, ddH2O 9.5μL; PCR amplification program: pre-denaturation 94°5min, deformation 94℃30s, annealing 52℃30s, extension 72℃2min (35 cycles), post-extension 72℃5min, and storage at 4°; the unpurified product was sent to Jinweizhi Biotechnology Co., Ltd. for sequencing. The 16S rRNA sequence fed back by the sequencing results was compared with the GenBank on NCBI to determine the bacterial species. Search the NCBI for sequences with similarity to which genus. If the sequence is more than 97%, it is considered to belong to the same genus, and if the sequence is more than 99%, it is considered to belong to the same species. Use MEGA 11 to construct a phylogenetic tree based on the sequence. Refer to "Lactic Acid Bacteria Classification and Identification and Test Methods" and "Bergey Bacteria Identification Manual" and use according to the instructions of the lactic acid bacteria identification biochemical tube.
[0036] Table 1 Physiological and biochemical identification table
[0037]
[0038] Depend on Figure 2 As can be seen from Table 1, bacterial microscope pictures show that bacterial strain 11 is short rod-shaped and is Gram-positive bacteria, and colony characteristics are smooth on the surface, and the milky white color of circular protrusion. As can be seen from the table, by contrasting bacterial strain 11, mannose and sorbitol cannot be utilized, and all the other sugars can be utilized, and the most likely lactobacillus gasseri of bacterial strain 11 is shown by the identification table. The obtained strain sequence is found through Blast comparison analysis, and it and lactobacillus gasseri have a similarity of 99% on 16S rDNA sequence. The 16S gene sequence of lactobacillus gasseri and the 16S gene sequence of related genus species are constructed into a phylogenetic tree, and it is observed that bacterial strain 11 and lactobacillus gasseri (Lactobacillus gasseri) are in the same branch on the branch, and in conjunction with NCBI comparison result and physiological and biochemical identification result, it is determined that probiotic strain Y11 is lactobacillus gasseri, and is named after LactobacillusgasseriY11.
[0039] Example 3: Mice grouping and the effects of synbiotics on body weight, fasting blood glucose and oral glucose tolerance in mice
[0040] The screened Lactobacillus gasseri Y11 was inoculated into MRS at a 1% inoculum amount and activated for three generations at 37°C for 14 hours. The mixture was centrifuged at 8000 r / min for 5 minutes, washed three times with 0.85% saline, and then resuspended in saline for live bacteria counting. The live bacteria count was measured to be 1×109 CFU / mL when OD600 nm was 1.8, and it was used as a probiotic for animal gavage.
[0041] 60 male mice (C57BL / 6J), SPF grade, weighing 20±2g, 5 weeks old, were purchased from Sibeifu Biological Co., Ltd. The animal laboratory met the SPF grade hygiene standards (temperature: 22℃±2℃, humidity: 55%±5%, 12-h light / dark cycle) and had free access to food and water throughout the study. Water, bedding, and feed were changed every day. The ordinary feed and diabetic feed used in the experiment were purchased from Sibeifu Biotechnology Co., Ltd. The diabetic feed consisted of 67% basal feed, 10% lard, 20% sucrose, 2.5% cholesterol, and 0.5% sodium cholate. All animal experiments in this study were carried out in accordance with the principles and guidelines established by the Animal Care and Use Ethics Committee of Hebei Agricultural University, and the animal license number was SCXK (Beijing) 2019-0010.
[0042] After one week of adaptation, 10 mice were selected as the normal group (n=10) and fed with normal feed, and the remaining 50 mice were selected as the HFD model group and fed with diabetic feed. After 4 weeks of feeding, all mice were fasted for 12 hours, and STZ (100 mg / kg, 0.1 mol / L citric acid buffer pH 4.4) was injected intraperitoneally in the HFD group, and the same volume of citric acid buffer was injected intraperitoneally in the normal group. After 72 hours, the fasting blood glucose level (FBG) was measured to be greater than 11.1 mmol / L for three consecutive days, and the mice with symptoms such as three more and one less (polydipsia, polyphagia, polyuria) and obvious weight loss were considered to be successfully modeled. After that, the HFD mice were divided into 5 groups: normal group, model group, drug group, probiotic group, prebiotic group, and synbiotic group. After 8 weeks of treatment, the mice were fasted overnight and then killed. Blood samples were collected and serum was obtained at 4℃3000r / min for 15 minutes. All tissues and organs were then stored at -80℃ for further analysis. Body weight and blood glucose were measured weekly during the experiment. In the last week of the experiment, mice were subjected to an oral glucose tolerance test. Oral glucose (2 g / kg of body weight) was administered after fasting for 12 h, and blood glucose levels were tested at 0, 15, 30, 60, 90, and 120 min using a blood glucose meter (Sino, China). The area under the curve (AUC) of blood glucose levels was calculated to assess glucose tolerance. Fasting blood glucose (FBG) was measured by blood sampling from the tail vein at the same time each week. The wound was disinfected before and after blood sampling to ensure hygiene to prevent infection.
[0043] In the first four weeks, the weight of mice in the six treatment groups gradually increased. It was found that the weight gain of the group fed with high-fat and high-sugar feed was greater than that of the normal group fed with normal feed, indicating a trend of weight gain. At the end of the fourth week, type II diabetic mice were modeled, and the normal group was intraperitoneally injected with equal volume fractions of citric acid buffer, and the high-fat group was intraperitoneally injected with streptozotocin for diabetes modeling. After modeling, it can be found in terms of body weight that the weight of the normal group continued to increase in the first week after intraperitoneal injection, that is, the fifth week, and the weight of the high-fat and high-sugar group decreased rapidly, which was significantly different from the normal group. It can be seen that the model was successfully modeled. From the weight chart a, in the last week after the intervention, there was a significant difference in weight between the synbiotic group, probiotic group, prebiotic group, metformin group and the model group, and the weight of the model group continued to decrease, proving that our intervention had a significant improvement in weight compared with the model group. Figure 3B From the weekly fasting blood glucose levels, we can see that the fasting blood glucose remained at the same level of about 5mmol / L in the first four weeks. After the fifth week of modeling, it was clearly observed that the fasting blood glucose of the modeling group began to gradually increase and was in a state of hyperglycemia, which once again proved that our modeling was successful. From the fifth week, interventions were carried out in different treatment groups, and the changes in fasting blood glucose were monitored weekly. Compared with the model group, from the 12th week, there was no significant difference in blood glucose between the metformin group and the synbiotic group, there was no significant difference between the probiotic group and the synbiotic group, and there was no significant difference between the prebiotic group and the probiotic group, but there was a significant difference compared with the model group, and the normal group always maintained a normal blood glucose state. Figure 3 C shows that in the last week of the oral glucose tolerance test, the blood sugar of the model group was always at a high level. The blood sugar of the normal group began to drop after 15 minutes until it returned to normal. The fastest recovery groups were the metformin group, synbiotic group, probiotic group, and prebiotic group. The model group recovered the slowest, indicating that insulin resistance had occurred. Figure d is the area under the curve calculated based on the oral glucose tolerance test. Compared with the model group, there was no difference between the metformin group and the synbiotic group, and there were significant differences between the probiotic group, prebiotic group, and synbiotic group (P < 0.05). The model group was most significantly different from the other groups (P < 0.05).
[0044] Example 4 Effects of Synbiotics on Biochemical Parameters in Mice
[0045] Serum insulin and glycosylated hemoglobin were measured using commercial enzyme-linked immunosorbent assay (ELISA) kits from Shanghai Yuanju Biotechnology Co., Ltd. (Shanghai, China). TG, TC, HDL-C, and LDL-C were measured using kits from Nanjing Urban Construction Bioengineering Institute. Insulin resistance index, insulin sensitivity index, and insulin secretion index were calculated based on fasting blood glucose and insulin.
[0046] Depend on Figure 4 It can be seen that after 12 weeks, the blood lipid level, glycosylated hemoglobin and fasting insulin content in the mouse serum were detected, and the blood lipid, insulin and glycosylated hemoglobin parameters of the mice were evaluated. Compared with the normal group, the levels of TG (2.08±0.52mmol / L) and TC (21.03±1.66mmol / L) in the serum of the model group were significantly increased, and the serum LDL-C (0.694±0.09mmol / L) level of the model group was significantly increased, and the HDL-C (3.77±0.53mmol / L) level was significantly decreased. It can be seen that the model group has severe lipid metabolism disorders. This phenomenon can be improved and alleviated after intervention. Figure 4A and 4B show that the synbiotic group can reduce the increase of TG (1.19±0.28mmol / L) and TC (14.49±1.89mmol / L) after intervention, and there is no significant difference compared with the normal group. The probiotic group and prebiotic group also significantly restored their increasing trend compared with the model group, indicating that the levels of TG and TC can be improved after intervention. Figure 4 C and 4D show that the LDL-C content in the model group increased significantly compared with the normal group and had a significant difference (P < 0.05). After intervention, the metformin group and the synbiotic group had no significant difference from the normal group. The HDL-C level was the lowest in the model group and the highest in the normal group, followed by the metformin group, the synbiotic group, the prebiotic group, and the probiotic group. Figure 4 E, 4F show that the content of serum glycosylated hemoglobin was detected by enzyme-linked immunosorbent assay kit and found that the model group had significant differences with other groups (P < 0.05), and the other groups could improve blood glucose homeostasis to varying degrees. There was no significant difference between the normal insulin level group and the metformin group. The fasting insulin content in the model group was the highest and the difference with other groups was the most obvious (P < 0.05). It can be seen that the model group had the worst insulin resistance. According to the index level calculated based on fasting blood glucose and insulin content, the figure shows that the model group had the worst insulin resistance. The synbiotic group could significantly reduce insulin resistance and had a similar effect to the metformin group. Among them, the probiotic and prebiotic groups could also restore the insulin resistance index level compared with the model group. From the perspective of QUICK1 insulin sensitivity index, there was a significant difference between the model group and other groups (P < 0.05), and different intervention groups could significantly improve insulin sensitivity. There was no significant difference in HOMA-β insulin secretion index between the intervention group and the intervention group (P < 0.05).
[0047] Example 5 H&E staining of mouse liver by synbiotics
[0048] Liver tissues were stained with hematoxylin and eosin (H&E) for histopathological analysis. Fixed liver samples were embedded in paraffin and cut into 5-micron thick sections. Images of liver tissues were obtained using an electron microscope at 100×, 400× magnification.
[0049] Depend on Figure 5It can be seen that by staining the liver tissue of each group of mice for histopathological observation, in the H&E staining sections, it can be observed that the liver tissue of the normal group showed a complete morphological structure, the hepatocyte nuclei were well arranged, and no pathological changes were observed. The hepatocytes of the mice in the model group were disordered, with fat vacuoles of varying sizes, enlarged cytoplasmic and nuclear spaces, and unclear central veins, revealing obvious fatty degeneration in the liver of mice. In contrast, the metformin group, synbiotic group, probiotics and prebiotic groups can significantly restore the relatively complete liver tissue structure and make the hepatocyte nuclei more neatly arranged. Among them, the metformin group and synbiotic group can significantly restore fat vacuoles, and the cell arrangement is also neater than that of the model group. Therefore, the intervention of the synbiotic group significantly reversed hepatic fatty degeneration and alleviated liver damage caused by diabetes. The ratio of the number of vacuoles to the vacuolar area in each group shows that the model group has the largest number of vacuoles and the vacuolar area accounts for a large proportion, which can indicate that the liver of the model group has undergone significant degeneration.
[0050] Example 6 Analysis of gene expression of mice by synbiotics
[0051] The tissue was ground and lysed using liquid nitrogen, and RNA was isolated using Trizol reagent (Tiangen Biotech, China) in an RNA-free centrifuge tube. The purity of sample RNA was determined using Nano Drop ND1461000 (Thermo Scientific Inc, USA), and cDNA was synthesized using the TransScript One-Step gDNA Removal and cDNA Synthesis SuperMix Kit (TransGenBiotech, China) according to the manufacturer's instructions, and quantified using LightCycler 96 (Roche, Switzerland) (Table 2).
[0052] Table 2 RT-qPCR primer names and sequences
[0053]
[0054]
[0055] Depend on Figure 6 It can be seen that the mRNA expression level of GIP in the ileum was significantly upregulated in the model group compared with the normal group, and there was no difference in the other groups; compared with the model group, the normal group, the metformin group and the prebiotic group were significantly downregulated; the expression level of GLP-1 was upregulated in the model group compared with the normal group (P < 0.05), but compared with the model group, the other groups were significantly downregulated and recovered. Since the activity of α-glucosidase is inhibited, the glucose level decreases, which in turn causes GIP to be downregulated. Since GIP can stimulate the expression of GLP-1, both of them are downregulated. Both of them have unique roles in regulating the mechanism of blood glucose homeostasis.
[0056] The lipid metabolism-related gene PPARγ in the liver can activate the key enzymes PEPCK and G6PASE related to liver gluconeogenesis, reducing the glucose produced by the liver and thus reducing liver glycogen output. In addition, overexpression of PPARγ can cause serious lipid metabolism disorders and increase insulin resistance.
[82] . Compared with the normal group, the mRNA expression level of PPARγ in the model group was significantly upregulated. After the intervention of synbiotics, the mRNA expression level of PPARγ was significantly downregulated, approaching the level of normal mice. Compared with the model group, the mRNA expression levels of gluconeogenesis-related genes in both the metformin group and the probiotic group were downregulated (P < 0.05), reducing liver gluconeogenesis and lowering blood sugar. For insulin secretion, when the GLUT-2 gene is missing, the cells will cause a decrease in insulin levels as blood sugar increases. Compared with the model group, the synbiotic group can significantly restore the expression of GLUT-2 (P < 0.01), indicating that the synergistic intervention of probiotics and XOS can increase the gene expression of GLUT-2 in diabetic mice. Compared with the normal group, the AMPK gene level in the model group was significantly upregulated, and the metformin group and the probiotic group could be significantly downregulated. Its activation can improve the metabolic imbalance caused by type II diabetes. Activating the MTOR-S6K1 pathway promotes the production of downstream molecules, allowing S6K1 to regulate cell growth, glucose and lipid metabolism, and protein synthesis.
[82] Compared with the normal group, the expression of MTOR and S6K1 genes in the model group was significantly upregulated (P<0.01), and compared with the model group, the expressions of MTOR and S6K1 genes in other groups were significantly downregulated (P<0.01).
[0057] Example 7 Analysis of the effect of synbiotics on intestinal flora of mice
[0058] The V3–V4 region of the 16S rRNA gene of each sample was PCR amplified using primers 338F and 806R, and the PCR products were subsequently sequenced using the IlluminaNovaSeq PE 250 platform (Illumina, USA). Clean tags were obtained after splicing and quality control of the PE raw materials sequenced by Illumina novaseq, and then chimera filtering was performed to obtain valid tags for further analysis. Valid tags for all samples with 97% identity were clustered into operational taxonomic units (OTUs).
[0059] In this example, fecal 16S rRNA sequencing analysis was performed to investigate the effects of synbiotics on the diabetic gut microbiota. Based on non-metric multidimensional scaling (NMDS) analysis at the operational taxonomic unit (OTU) level, the species composition of the probiotic, prebiotic, and synbiotic groups were closely clustered together. In contrast, the metformin group was significantly different from all other groups, with the greatest difference compared to the model group. β-diversity analysis further showed that the gut microbiota structure of the model group was different from the other groups, indicating the presence of microbial dysbiosis ( Figure 7 A). At the phylum level, seven dominant species were identified, among which the top three phylum-level species in abundance were Firmicutes, Bacteroidetes, and Verrucomicrobia, accounting for 90%. In the high-fat diet group, the abundance of Firmicutes increased, while the abundance of Bacteroidetes decreased, and the F / B ratio was higher than that of the control group. In contrast, the synbiotic group increased the abundance of Bacteroidetes and decreased the F / B ratio compared with the model group. Compared with the control group, the relative abundance of Verrucomicrobia decreased in the model group, while the abundance of Actinobacteria, Desulfovibrio, and Proteobacteria increased. Increased abundance of Desulfovibrio was associated with worsening inflammatory diseases, confirming the inflammation in the model group. Compared with the model group, the intervention group reversed the abundance of Verrucomicrobia and Proteobacteria ( Figure 7 B). At the genus level, 21 species with the highest relative abundance were detected, of which the top three in proportion were Dubosiella, Lactobacillus, and Akkermansia. By genus-level analysis and evaluation of the top 21 species by relative abundance, the relative abundance of Akkermansia increased in the intervention group compared with the model group. Synbiotics significantly increased the relative abundance of Bifidobacterium, indicating its potential in improving the onset of type 2 diabetes. In the model group, the relative abundance of Akkermansia and norank_f__Muribaculaceae was relatively low. The probiotic group reversed the relative abundance of Desulfobacteria, Proteobacteria, Turicibacter, Lachnoclostridium, and Romboutsia. In addition, the relative abundance of Proteobacteria and norank_f__Muribaculaceae was also reversed in the synbiotic group, indicating that synbiotics have a superior ability to regulate the differences in the intestinal microbiota of diabetic mice and increase the production of beneficial bacteria compared with other groups ( Figure 8 C).
[0060] Dubosiella, Lactobacillus, Akkermansia, and Norank_f__Muribaculaceae emerged as important genera in various treatment groups ( Figure 8 D). Mantel test results showed that there was a significant association between the composition of the intestinal microbiota at the genus level and biochemical parameters including triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), glycosylated hemoglobin (HbA1C), insulin (INS), homeostasis model assessment of insulin resistance index (HOMA-IR), QUICK1, homeostasis model assessment of β-cell function (HOMA-β), body weight (BW) and fasting blood glucose (FBG) (P<0.01)( Fig. 9E). Spearman correlation analysis indicated a potential relationship between the gut microbiota and biochemical parameters. Turicibacter, Romboutsia, Coriobacteriaceae_UCG-002, Dubosiella, Bifidobacterium, Klebsiella, and Weissella were positively correlated with HbA1C, INS, LDL-C, TC, HOMA-IR, TG, and FBG. In contrast, Faecalibaculum, Prevotellaceae_UCG-001, norank_f__norank_o__RF39, and Akkermansia were negatively correlated. norank_f__Ruminococcaceae and Alistipes were positively correlated with HOMA-β, and significant differences were observed ( Fig. 9 F).
[0061] Collectively, these findings suggest that synbiotics can improve gut microbiota dysbiosis induced by a high-fat diet / streptozotocin combination.
Claims
1. A youth-derived intestinal microorganism Lactobacillus gasseri Y11, characterized in that: The deposit number of the Lactobacillus gasseri Y11 is CGMCC No.31108.
2. Use of Lactobacillus gasseri Y11 according to claim 1 in the preparation of hypoglycemic drugs.
3. A hypoglycemic drug, characterized in that: The method comprises the Lactobacillus gasseri Y11 as claimed in claim 1.
4. A fermentation product, characterized in that Obtained by fermenting the Lactobacillus gasseri Y11 described in claim 1.
5. A prebiotic, characterized in that: The prebiotic contains the Lactobacillus gasseri Y11 and / or its fermentation product as claimed in claim 1.
Citation Information
Patent Citations
Compound microbial inoculant having immunoregulation function as well as preparation method and application of compound microbial inoculant
CN109161494A
Lactobacillus gasseri and application thereof in relieving and treating hyperuricemia
CN112458027A
Lactobacillus gasseri SHMB 0001 and application thereof in preventing and relieving acute colitis
CN117025479A
Lactobacillus gasseri MY5 and application of lactobacillus gasseri MY5 in preparation of anti-inflammatory, bowel-relaxing and intestine-protecting food and medicine
CN117343875A
Lactobacillus gasseri for relieving symptoms of diabetes and application of lactobacillus gasseri
CN117487692A
